Data protection Impressum

Neuroscience

Three Geneva companies have received funding from the FIF, the canton of Geneva's innovation financing program: CHF 400,000 in FIF Growth funding for Goodwall, CHF 50,000 in FIF Seed Tech funding for Roofless Labs, and a CHF 50,000 FIF Grant for Infera Neuro.

Goodwall, Roofless Labs and Infera Neuro awarded FIF funding

8 September 2026

Addex Therapeutics, the Geneva-based clinical-stage biotech developing small-molecule allosteric modulators for neurological disorders, has raised gross proceeds of USD 2.8 million through its at-the-market program.

Addex Therapeutics extends its cash runway into the fourth quarter of 2027

31 August 2026

Bewe, a University of Fribourg spin-off developing a neuroscience-based digital intervention for unhealthy food cravings, has been awarded Biopôle's Pre-Clinical Top-Up, a CHF 250,000 convertible loan supporting start-ups facing high clinical validation costs.

Bewe awarded the Biopôle Pre-Clinical Top-Up for its digital therapy against food cravings

20 August 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (July 2026)

3 August 2026

The .NeuroRestore center in Lausanne, led by Jocelyne Bloch and Grégoire Courtine, has been honored with the 2026 Grand Prix scientifique of the NRJ Foundation - Institut de France for its brain-spine interface that restores movement to paralyzed patients.

.NeuroRestore wins part of France’s 2026 NRJ Foundation science grand prix

13 July 2026

Geneva has been named European Capital of Brain Health 2026 by the European Academy of Neurology, in recognition of its research and innovation ecosystem.

Geneva named European Capital of Brain Health 2026

6 July 2026

AC Immune will receive a USD 4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the Phase 2 VacSYn trial of ACI-7104, its immunotherapy for early Parkinson's disease.

AC Immune secures USD 4 million grant to advance its Parkinson’s immunotherapy

6 July 2026

An EPFL team has created MiCRo, a new large language model structured like the human brain, with four specialized modules that give users more control and move away from “black box” AI.

EPFL researchers build a brain-inspired AI model that is more transparent and controllable

29 June 2026

Geneva-based MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group, funding the expansion of its U.S. commercial operations and opening the door to a potential combination of neurotherapeutics and artificial intelligence.

MindMaze secures CHF 8 million to expand its neurotherapeutics platform

1 June 2026

Geneva's Neurosoft Bioelectronics has raised USD 7.5 million in an oversubscribed seed round to advance its brain interface platform and build a cortical AI model.

Neurosoft Bioelectronics raises USD 7.5 million to advance its brain interface platform

26 May 2026

1 2 3